drugset / Trial / NCT00075829

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

NCT00075829

RandomizedCrossoverOpen-labelTreatment

Summary

The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant. Study subjects will be biologically assigned to the appropriate arm depending on the availability of an HLA-matched sibling. There is a nested randomized phase III trial of observation versus maintenance therapy following the second autologous transplant for patients on the tandem autologous transplant arm.

Timeline

Start
2003-12
Primary completion
2012-06
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexamethasone Small molecule 40 mg
Comparator Thalidomide Other / unclassified 200 mg

Indications